Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat [Yahoo! Finance]
Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share (AMRN)
Last amarin corporation plc - american depositary shares, each representing one ordinary share earnings: 4/30 05:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.amarincorp.com/investors
Company Research
Source: Yahoo! Finance
The company recorded an adjusted loss of 4 cents per share in the year-ago quarter. Total revenues were $67.5 million, which beat the Zacks Consensus Estimate of $46 million. However, revenues declined 16% from the year-ago quarter's levels, owing to lower product revenues. Despite the better-than-expected results, shares of Amarin were down 12.9% on Jul 31. Year to date, the stock has plunged 21.6% compared with the industry's decline of 0.1%. Image Source: Zacks Investment Research Quarter in Detail Net product revenues from Vascepa, the company's sole marketed drug, in the second quarter, were $47.5 million, down 27.1% year over year. U.S. product revenues from Vascepa totaled $43.8 million, declining 32.2% from the year-ago quarter's level as rising generic competition continued to hurt sales volumes. The drug's U.S. sales beat our model estimate of $32.1 million. Product revenues from Vazkepa (Vascepa's brand name in Europe) in the European market totaled $3.5 milli
Show less
Read more
Impact Snapshot
Event Time:
AMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMRN alerts
High impacting Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share news events
Weekly update
A roundup of the hottest topics
AMRN
News
- Amarin Announces Two Upcoming Investor EventsGlobeNewswire
- Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal OfficerBusiness Wire
- Affinia Therapeutics Announces the Appointment of Rami Daoud as Chief Business and Financial OfficerPR Newswire
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual EuropeGlobeNewswire
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) CongressGlobeNewswire
AMRN
Earnings
- 7/31/24 - Beat
AMRN
Sec Filings
- 8/5/24 - Form 4
- 8/1/24 - Form 4
- 8/1/24 - Form 4
- AMRN's page on the SEC website